Informativa su Privacy e Cookies
Questo sito utilizza cookie tecnici funzionali, cookie analitici di terze parti anonimizzati, e cookie di terze parti che potrebbero profilare: accedendo a qualunque elemento/area del sito al di fuori di questo banner, acconsenti a ricevere i cookie secondo le tue Preferenze. Puoi liberamente consentire, negare o impostare le tue preferenze sull\'utilizzo dei Cookies tramite i link di seguito. Se vuoi saperne di più puoi consultare la pagina Informazioni su Privacy e Cookies. Ti ricordo che i Cookies saranno registrati sul tuo browser solo a seguito del tuo consenso e secondo la modalità tecniche consentite dai produttori software, puoi liberamente cancellare i Cookies in qualsiasi momento tramite l\'apposita funzione del tuo browser.  Se non consenti l\'utilizzo di alcuni Cookies si potrebbero verificare malfunzionamenti delle pagine web oppure alcuni contenuti potrebbero non funzionare. [user_consent_state] [cookie_audit columns=\"cookie,description\" heading=\"The below list details the cookies used in our website.\"]
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

No cookies to display.

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

No cookies to display.

[Corrections] Correction to Lancet Infect Dis 2024; published online Dec 18. https://doi.org/10.1016/S1473-3099(24)00730-8

Di |2025-01-09T00:30:01+01:00Gennaio 9th, 2025|Categorie: Coronavirus Lancet|

Dondorp AM. MMV533, a promising new antimalarial on the horizon. Lancet Infect Dis 2024; published online Dec 18. https://doi.org/10.1016/S1473-3099(24)00730-8—In this Comment, the fourth sentence of the second paragraph should read “…at 20 mg, which i...

[Comment] Hecolin vaccination strategies for hepatitis E outbreak control in resource-constrained settings

Di |2025-01-09T00:30:01+01:00Gennaio 9th, 2025|Categorie: Coronavirus Lancet|

Hepatitis E virus (HEV), a leading cause of acute viral hepatitis globally, disproportionately impacts low-income countries through genotypes 1 and 2. These HEV genotypes, primarily transmitted via contaminated water and food, are associated with high ...

[Articles] Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial

Di |2025-01-09T00:30:01+01:00Gennaio 9th, 2025|Categorie: Coronavirus Lancet|

Multi-age cohort campaigns had a marked effect on vaccine-type carriage and fractional-dose campaigns met non-inferiority criteria. Such campaigns should be considered in low-coverage settings, including humanitarian emergencies, to accelerate populati...

[Comment] A new RH5.1/Matrix-M candidate malaria vaccine: a promising finding to boost malaria elimination in Africa

Di |2025-01-08T00:30:02+01:00Gennaio 8th, 2025|Categorie: Coronavirus Lancet|

Hamtandi M Natama and colleagues conducted a clinical trial on the efficacy and safety of the RH5.1/Matrix-M vaccine, a candidate malaria vaccine, in children aged 5–17 months in Burkina Faso and published its interim results in The Lancet Infectious D...

[Comment] A new RH5.1/Matrix-M candidate malaria vaccine: a promising finding to boost malaria elimination in Africa

Di |2025-01-08T00:30:02+01:00Gennaio 8th, 2025|Categorie: Coronavirus Lancet|

Hamtandi M Natama and colleagues conducted a clinical trial on the efficacy and safety of the RH5.1/Matrix-M vaccine, a candidate malaria vaccine, in children aged 5–17 months in Burkina Faso and published its interim results in The Lancet Infectious D...

[Corrections] Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7

Di |2025-01-08T00:30:02+01:00Gennaio 8th, 2025|Categorie: Coronavirus Lancet|

Garcia Quesada M, Peterson ME, Bennett JC, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. ...

[Corrections] Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7

Di |2025-01-08T00:30:02+01:00Gennaio 8th, 2025|Categorie: Coronavirus Lancet|

Garcia Quesada M, Peterson ME, Bennett JC, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. ...

[Correspondence] Additional questions regarding transfusion-transmitted dengue virus in Brazil – Authors’ reply

Di |2025-01-07T00:30:02+01:00Gennaio 7th, 2025|Categorie: Coronavirus Lancet|

We appreciate the interest and thoughtful analysis by Silvano Wendel and colleagues of our Correspondence regarding the risk of transfusion-transmitted dengue virus (TT-DENV) during Brazil's largest recorded dengue outbreak.1 We value the opportunity t...

[Correspondence] Additional questions regarding transfusion-transmitted dengue virus in Brazil – Authors’ reply

Di |2025-01-07T00:30:02+01:00Gennaio 7th, 2025|Categorie: Coronavirus Lancet|

We appreciate the interest and thoughtful analysis by Silvano Wendel and colleagues of our Correspondence regarding the risk of transfusion-transmitted dengue virus (TT-DENV) during Brazil's largest recorded dengue outbreak.1 We value the opportunity t...

[Correspondence] Additional questions regarding transfusion-transmitted dengue virus in Brazil

Di |2025-01-07T00:30:01+01:00Gennaio 7th, 2025|Categorie: Coronavirus Lancet|

We read the Correspondence by Flávia Jacqueline Almeida and colleagues1 with interest. Dengue has affected millions of people annually, with many asymptomatic cases, where the likelihood of viraemic (RNAaemic) blood donors cannot be disregarded.

[Correspondence] Additional questions regarding transfusion-transmitted dengue virus in Brazil

Di |2025-01-07T00:30:01+01:00Gennaio 7th, 2025|Categorie: Coronavirus Lancet|

We read the Correspondence by Flávia Jacqueline Almeida and colleagues1 with interest. Dengue has affected millions of people annually, with many asymptomatic cases, where the likelihood of viraemic (RNAaemic) blood donors cannot be disregarded.

Torna in cima